COR

abc-202602020001140859false00011408592026-02-022026-02-020001140859us-gaap:CommonStockMember2026-02-022026-02-020001140859abc:A5000002.875SeniorNotesDue2028Member2026-02-022026-02-020001140859abc:A5000003.625SeniorNotesDue2032Member2026-02-022026-02-02

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 2, 2026

Cencora, Inc. (Exact name of registrant as specified in its charter)

Commission File Number: 1-16671

Delaware 23-3079390 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.)

1 West First AvenueConshohockenPA 19428-1800 (Address of principal executive offices) (Zip Code)

(610) 727-7000 (Registrant’s telephone number, including area code) Not Applicable (Former name or former address, if changed since last report.) Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of exchange on which registered Common stockCORNew York Stock Exchange(NYSE) 2.875% Senior Notes due 2028COR28New York Stock Exchange(NYSE) 3.625% Senior Notes due 2032COR32New York Stock Exchange(NYSE)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02. Results of Operations and Financial Condition. On February 4, 2026 Cencora, Inc. (the “Company”) issued a news release announcing the Company’s earnings for the fiscal quarter ended December 31, 2025. A copy of the news release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Current Report, including the exhibit attached hereto as Exhibit 99.1 and the information under Item 7.01 below, is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 7.01. Regulation FD Disclosure. On February 2, 2026, the Company acquired the majority of the outstanding equity interests that it did not previously own in OneOncology, a physician-led national platform empowering independent medical specialty practices rooted in oncology for a total cash consideration of approximately $4.6 billion. OneOncology’s affiliated practices and management retained a minority interest in OneOncology. The Company funded the transaction through new debt financing. OneOncology’s future operating results will be consolidated as a component of the U.S. Healthcare Solutions reportable segment. On February 4, 2026, the Company is conducting a conference call and webcast scheduled to be held at 8:30 a.m. Eastern time regarding its results for the fiscal quarter ended December 31, 2025 and related matters. A link to the conference call and slides prepared for the conference call are available on the Company's website at investor.cencora.com.

Item 9.01. Financial Statements and Exhibits. (d)  Exhibits.

Exhibit NumberDescription 99.1News Release of Cencora, Inc. dated February 4, 2026

104Cover Page Interactive Data File (formatted as inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CENCORA, INC.

Date: February 4, 2026By:/s/ James F. Cleary Name:James F. Cleary Title:Executive Vice President & Chief Financial Officer

abc-202511050001140859false00011408592025-11-052025-11-050001140859us-gaap:CommonStockMember2025-11-052025-11-050001140859abc:A5000002.875SeniorNotesDue2028Member2025-11-052025-11-050001140859abc:A5000003.625SeniorNotesDue2032Member2025-11-052025-11-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 5, 2025

Cencora, Inc. (Exact name of registrant as specified in its charter)

Commission File Number: 1-16671

Delaware 23-3079390 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.)

1 West First AvenueConshohockenPA 19428-1800 (Address of principal executive offices) (Zip Code)

(610) 727-7000 (Registrant’s telephone number, including area code) Not Applicable (Former name or former address, if changed since last report.) Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of exchange on which registered Common stockCORNew York Stock Exchange(NYSE) 2.875% Senior Notes due 2028COR28New York Stock Exchange(NYSE) 3.625% Senior Notes due 2032COR32New York Stock Exchange(NYSE)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02. Results of Operations and Financial Condition.

Earnings Release for the Fiscal Quarter and Year Ended September 30, 2025

On November 5, 2025, Cencora, Inc. (the “Company”) issued a news release announcing the Company’s earnings for the fiscal quarter and year ended September 30, 2025. A copy of the news release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

New Reporting Structure Recently, Cencora undertook a strategic review of its business to ensure alignment with its growth priorities and strategic drivers. As a result of this review, the Company has reorganized certain business components within its reporting structure. Beginning in the first quarter of fiscal 2026, the Company's reporting structure will be comprised of U.S. Healthcare Solutions, International Healthcare Solutions, and Other. The U.S. Healthcare Solutions reportable segment will consist of U.S. Human Health (excluding legacy U.S. Consulting Services). The International Healthcare Solutions reportable segment will consist of Alliance Healthcare, Innomar, World Courier, and strategic components of PharmaLex. Other, which is not considered a reportable segment, will consist of businesses for which the Company has begun to explore strategic alternatives and includes MWI Animal Health, Profarma, U.S. Consulting Services and the other components of PharmaLex. In the attached Exhibit 99.2, which is incorporated herein by reference, the Company is voluntarily furnishing a supplemental disclosure of unaudited revised reportable segment information for each of the quarters of fiscal 2025 and 2024 and the fiscal years ended September 30, 2025 and 2024 under the reporting structure that is expected to be utilized in fiscal 2026 to assist investors in analyzing the changes to its reporting structure. The information in this Current Report, including the exhibits attached hereto as Exhibit 99.1 and Exhibit 99.2 and the information under Item 7.01 below, is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 7.

abc-202508060001140859false00011408592025-08-062025-08-060001140859us-gaap:CommonStockMember2025-08-062025-08-060001140859abc:A5000002.875SeniorNotesDue2028Member2025-08-062025-08-060001140859abc:A5000003.625SeniorNotesDue2032Member2025-08-062025-08-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 6, 2025

Cencora, Inc. (Exact name of registrant as specified in its charter)

Commission File Number: 1-16671

Delaware 23-3079390 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.)

1 West First AvenueConshohockenPA 19428-1800 (Address of principal executive offices) (Zip Code)

(610) 727-7000 (Registrant’s telephone number, including area code) Not Applicable (Former name or former address, if changed since last report.) Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of exchange on which registered Common stockCORNew York Stock Exchange(NYSE) 2.875% Senior Notes due 2028COR28New York Stock Exchange(NYSE) 3.625% Senior Notes due 2032COR32New York Stock Exchange(NYSE)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02. Results of Operations and Financial Condition. On August 6, 2025, Cencora, Inc. (the “Company”) issued a news release announcing the Company’s earnings for the fiscal quarter ended June 30, 2025. A copy of the news release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Current Report, including the exhibit attached hereto as Exhibit 99.1 and the information under Item 7.01 below, is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 7.01. Regulation FD Disclosure. On August 6, 2025, the Company issued a news release announcing that it is conducting a conference call and webcast scheduled to be held at 8:30 a.m. Eastern time regarding its results for the fiscal quarter ended June 30, 2025 and related matters. A link to the conference call and slides prepared for the conference call are available on the Company's website at investor.cencora.com.

Item 9.01. Financial Statements and Exhibits. (d)  Exhibits.

Exhibit NumberDescription 99.1News Release of Cencora, Inc. dated August 6, 2025

104Cover Page Interactive Data File (formatted as inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CENCORA, INC.

Date: August 6, 2025By:/s/ James F. Cleary Name:James F. Cleary Title:Executive Vice President & Chief Financial Officer